A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 Administered to Healthy Adult Volunteers
Latest Information Update: 24 Jun 2024
At a glance
- Drugs VXA G1.1 NN (Primary)
- Indications Norovirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Vaxart
Most Recent Events
- 27 Apr 2022 Status changed from recruiting to completed.
- 02 Feb 2022 New trial record